文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

新辅助雄激素剥夺治疗联合放疗对前列腺癌局灶推量的影像学纵向评估:ADT-RT-IEL 试验方案与早期结果

Androgen Deprivation Therapy and Radiation Therapy With Imaging Evaluation Longitudinally Trial: Protocol, Early Results, and Implications of Neoadjuvant Androgen Deprivation Therapy for Focal Radiation Therapy Boost in Prostate Cancer.
PubMed 文献 · Pract Radiat Oncol · 2026-09-29

ADT-RT-IEL 是一项前瞻性 2 期试验,评估定量 MRI 生物标志物 RSIrs 在局限期前列腺癌患者接受 ADT 联合放疗过程中的变化。97 例患者入组,新辅助 ADT 后 40% 病灶不可见,可见病灶中位缩小 55.8%,病灶内最大 RSIrs 均值从治疗前 329 降至 ADT 后 209、放疗后 107。初步提示 RSIrs 变化可能反映肿瘤反应,主要终点结果待随访。

要点

  • 新辅助 ADT 后 40% 的 PI-RADS 病灶不可见,前列腺体积中位缩小 21.5%。
  • 可见病灶在新辅助 ADT 后中位缩小 55.8%(IQR 42.8%-69.0%)。
  • 病灶内最大 RSIrs 均值从治疗前 329 降至 ADT 后 209 和放疗后 107。

核心结论

  • ADT-RT-IEL 试验已完成入组,初步结果显示治疗后 RSIrs 发生变化,可能提示肿瘤反应。
  • 新辅助 ADT 后部分病灶不可见,提示局灶放疗推量前可能需要同时参考 ADT 前和 ADT 后 MRI。
  • 主要终点结果将在达到主要终点时报告,目前随访仍在进行以评估影像反应与未来复发的关系。

研究设计与样本

  • 前瞻性 2 期 ADT-RT-IEL 试验,纳入 97 例符合入组标准的不利中危或高危局限期前列腺癌患者。
  • 患者接受根治性放疗联合 ADT,并在治疗前、新辅助 ADT 后放疗前、放疗后三个时间点行 MRI-RSI 采集。
  • 主要目的是评估 RSIrs 识别早期生化复发患者的表现,主要自变量为 ADT 和放疗后肿瘤内 RSIrs 变化。

主要发现

  • 97 例患者中 88 例可见 PI-RADS 病灶,其中 80 例有 1 个病灶、8 例有 2 个病灶。
  • 新辅助 ADT 后 40% 的病灶不可见,可见病灶中位缩小 55.8%(IQR 42.8%-69.0%)。
  • 前列腺体积中位缩小 21.5%(IQR 11.9%-31.6%)。
  • 病灶内最大 RSIrs 均值从 ADT 前 329(SD 185)降至放疗前 209(SD 125)和放疗后 107(SD 61)。

临床怎么用

  • 新辅助 ADT 后部分病灶不可见且可见病灶明显缩小,局灶放疗推量时宜同时参考 ADT 前和 ADT 后 MRI 以准确勾画。
  • 同时开始 ADT 和放疗可能有助于准确勾画大体肿瘤体积。
  • RSIrs 作为定量 MRI 生物标志物,其治疗中的变化可能用于评估肿瘤反应,但目前仍在研究阶段。

局限性

  • 当前报告为方案与早期结果,随访仍在进行,影像反应与未来复发的关系尚未确定。
  • 主要终点结果尚未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Men with aggressive, localized prostate cancer (PC) undergo definitive radiation therapy (RT) with androgen deprivation therapy (ADT). The prospective, phase 2 ADT and RT with Imaging Evaluation Longitudinally trial evaluates a quantitative magnetic resonance imaging (MRI) biomarker, Restriction Spectrum Imaging restriction score (RSIrs), at 3 time points (before treatment, after ADT, and after RT) for treatment response assessment. RSIrs is correlated with high-grade PC. METHODS AND MATERIALS: Men with unfavorable intermediate-risk or high-risk localized PC undergo definitive RT with ADT, and MRI-RSI acquisitions are obtained before therapy, after neoadjuvant ADT but before RT, and after RT. The primary aim is to evaluate the performance of RSIrs for identifying patients who will experience early biochemical recurrence. Change in RSIrs within tumors after ADT and RT is the primary independent variable. RESULTS: A total of 97 patients met the inclusion criteria. Visible Prostate Imaging Reporting and Data System lesions were identified in 88 patients: 80 patients had 1 lesion, and 8 patients had 2 lesions. After neoadjuvant ADT, 40% of lesions were not visible. Visible lesions shrank by a median of 55.8% (IQR, 42.8%-69.0%), whereas prostate volume decreased by 21.5% (11.9%-31.6%). The maximum RSIrs within lesions decreased from a mean of 329 (SD, 185) pre-ADT to 209 (SD, 125) pre-RT and 107 (SD, 61) post-RT. Follow-up is ongoing to assess whether imaging response is related to future recurrence. CONCLUSIONS: ADT and RT with Imaging Evaluation Longitudinally trial has completed accrual, and preliminary results demonstrate changes in RSIrs after treatment, which may indicate tumor response. Primary results will be presented when the primary endpoint is reached. With neoadjuvant ADT, both pre- and post-ADT MRI are likely necessary for an accurate focal RT boost. Concurrent commencement of ADT and RT facilitates accurate gross tumor volume delineation.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Song Y, Rojo Domingo M, Nguyen L, et al. Androgen Deprivation Therapy and Radiation Therapy With Imaging Evaluation Longitudinally Trial: Protocol, Early Results, and Implications of Neoadjuvant Androgen Deprivation Therapy for Focal Radiation Therapy Boost in Prostate Cancer. Pract Radiat Oncol. 2026. PMID: 42810618. doi:10.1016/j.prro.2026.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。